Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Question? After today's run has any long termer ever questioned their investment over the past 10 or 12 years, in which, mostly being a bull market for every other stock that they owned. Was holding worth it? But most important. Who is staying after today? Just Curious
(Humor)When Fish retired from Ihub I think Vegas put the over/under betting odds at 10 days. Who won money and who lost?
For the record I've been out of this for around 8-10 years but still follow this board. Like company but hate the stock
I wish there was a like button for this post
What about Trumps one time only offer, to all company's, to bring back overseas money for only a 10% tax? Sounds like he's giving all company's even more incentive to bring all the cash back. It's a one time only offer at 10%. I personally hope it brings a couple of trillion dollars back into our country.
Singapore, December 23, 2014 - Zecotek Photonics Inc. (TSX-V: ZMS; Frankfurt: W1I), a developer of leading-edge photonics technologies for industrial, healthcare and scientific markets, today announced that its subsidiary, Zecotek Imaging Systems Pte. Ltd., has settled its lawsuit against Philips and Saint Gobain, as parties in a legal proceeding started in February 2012 in connection with an alleged infringement of Zecotek`s patents on LFS scintillation crystals used in positron emission tomography (PET) imaging systems.
“Zecotek and Philips have identified areas of cooperation in the field of medical imaging,” said Dr. A.F. Zerrouk, Chairman, President, and CEO of Zecotek Photonics Inc. “We look forward to establishing a meaningful business relationship with Philips.”
The Company also announced that Zecotek Imaging Systems PTE. LTD. and Saint-Gobain Ceramics & Plastics, Inc. have reached an agreement to dismiss their pending lawsuit, pursuant to which Zecotek has given Saint-Gobain a covenant not to sue on U.S. Patent No. 7,132,060. The parties will undertake to dismiss with prejudice all asserted claims and counterclaims against one another. The terms of resolution of this lawsuit shall remain confidential.
Singapore, December 23, 2014 - Zecotek Photonics Inc. (TSX-V: ZMS; Frankfurt: W1I), a developer of leading-edge photonics technologies for industrial, healthcare and scientific markets, today announced that its subsidiary, Zecotek Imaging Systems Pte. Ltd., has settled its lawsuit against Philips and Saint Gobain, as parties in a legal proceeding started in February 2012 in connection with an alleged infringement of Zecotek`s patents on LFS scintillation crystals used in positron emission tomography (PET) imaging systems.
“Zecotek and Philips have identified areas of cooperation in the field of medical imaging,” said Dr. A.F. Zerrouk, Chairman, President, and CEO of Zecotek Photonics Inc. “We look forward to establishing a meaningful business relationship with Philips.”
The Company also announced that Zecotek Imaging Systems PTE. LTD. and Saint-Gobain Ceramics & Plastics, Inc. have reached an agreement to dismiss their pending lawsuit, pursuant to which Zecotek has given Saint-Gobain a covenant not to sue on U.S. Patent No. 7,132,060. The parties will undertake to dismiss with prejudice all asserted claims and counterclaims against one another. The terms of resolution of this lawsuit shall remain confidential.
You didn't get in late. I got in big time at .77 and some more at .49
I've got the symbol on Scottrade.
What is a good entry point because I can't see a chart of how high it's climbed since it started trading.
I've been reading posts on how it's been on fire for a week. Don't want to get in right before a pullback.
Graphene 3D Lab Inc GPHBF:Grey Market (Common Stock)A table providing an overview of the stock
Bid | Size -- | --
Ask | Size -- | --
Price Open 1.70
Previous Close 1.9192
Day High 1.70
Day Low 1.65
52 Week High 9/4/2014 | 1.9695
52 Week Low 9/4/2014 | 1.65
% Off 52 Week High -15.76%
% Off 52 Week Low 0.56%
Beta (5 Yr) --
Volatility Avg -- | --
10-Day Avg. Volume 0
Market data is in Real-time.
collapse, right-facing arrow indicating collapsed view of sectionFundamentals
A table providing the fundamentals of the stock
EPS (TTM) 4/30/2014 | -0.14
P/E Ratio 4/30/2014 | --
Market Cap --
Shares Outstanding --
Float 17.2M
Let's hope for a favorable ruling. I bought a bunch at .77
At the upcoming conference on April 10, Organovo will provide information on several topics, including:
KOL update: guidance on expectations and timelines for key opinion leader (KOL) evaluation of Organovo's 3D Liver tissue;
Cash burn and R&D spending: Review of the company's cash position and expectations of future spending;
Update on progress of bioprinted breast cancer models: New results from Organovo's bioprinted breast cancer models are expected to be released at the upcoming American Association for Cancer Research (AACR) annual meeting, to be held April 5-9 in San Diego, CA. Mr. Murphy will review the results on the live investor conference on April 10;
Advantages of NovoGen 3D Bioprinting versus currently available methods and technologies: Organovo will cover the advantages of its NovoGen 3D Bioprinting to achieve breakthroughs in the creation of living tissue, including up to date data from its 3D Liver product. Based on the performance of the liver to date, which will be reviewed at the conference, the company believes its human liver model currently in development has the opportunity to redefine the category of in vitro assays as being fully human; multicellular; three dimensional in size, shape, and substance; and consistent in form and function with a native tissue sample. It also believes this set of attributes is unique and umatched by current products and technologies, none of which use any form of bioprinting today.
I found this post on the stockhouse message board. Don't know where they found it or if it's true but I like seeing that they are exceeding the previous forecast.
Here is the post
Hamamatsu's sales in the Medical market will help ZMS
Main factor of the revisions of forecast
Notice on Revisions of Non-cosolidated Forecast
We have made the following revisions (B) on our non-consolidated forecast for the first six months of the fiscal
year ending September 30, 2014, which was announced on November 11, 2013 (A).
Note: The above forecast has been prepared based on the information which is currently available at this moment.
Actual results may differ from the forecast due to various factors that may arise in the future.
The non-consolidated business performance for the first six months of this fiscal year has slightly exceeded its
forecast announced earlier this fiscal year. Orders in the medical and industrial instrument markets, mainly in
Japan, have been doing especially well since the beginning of this year. Therefore, we expected to see an
increase in sales and profits compared with the previous forecast announced on November 11, 2013.
We continue to examine the non-consolidated forecast projected for the whole fiscal year in light of global
uncertainties such as the economic trend in Europe and the United States.
Zecotek Receives Another US Patent - MAPD
http://www.zecotek.com/EN/426/
Arcam Completes Acquisition of powder producer AP & C in Canada
Arcam AB, listed on NASDAQ OMX, has completed the acquisition of the powder division, AP & C
from Raymor Industries Inc for a total of 35 million Canadian dollars ("CAD").
The total purchase price amounts to 35 MCAD divided into an initial cash
payment of 20 MCAD at closing and an additional payment of total
maximum of 15 MCAD paid in 2015 and 2016, subject to certain
objectives.
AP & C revenue was approximately 6.5 MCAD with an EBITDA of about 1.5 MCAD in 2013. It
acquired business, currently has 31 employees, will become a subsidiary of
Arcam Group and the current management team continues today.
The acquisition is expected to contribute to increased net income per share in 2014.
AP & C manufactures metal powders using a proprietary technology for plasma
Atomization and titanium powder is today the largest product. A significant
part of AP & C's sales go to 3D printing. Other markets are Metal
Injection Molding (MIM), powders for plasma spraying and powder for HIPade
components. Arcam and AP & C will further develop and refine the plasma
Technology to continue to rapidly grow the company.
"AP & C's technology and market position in metal fabrication is a
perfect complement to Arcam machine sales and strengthens Arcam position
in Additive Manufacturing ", says Magnus René, CEO of Arcam.
This is information that Arcam AB (publ) is required to disclose under the
securities market and / or the Trading in Financial Instruments.
This information was published on February 12th 20134th
The price is getting away from me. Up 25% now. Still can't buy with no bid or ask. How high can it go to still be a good buy?
Unable to enter the order because no bid or ask price could be found for the symbol you entered.
That's what I get to my limit order request.
Unfortunately still no bid/ask on Scottrade this morning. Just have to watch it climb higher for now.
Full Story
SAN DIEGO, Jan. 29, 2014 /PRNewswire/ -- Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, today announced that it has performed its first 3D Liver tissue delivery.
The achievement marks the delivery of Organovo's 3D Liver tissue to a laboratory outside of the company to a key opinion leader (KOL) for experimentation, and marks the achievement of a milestone along the pathway to commercial launch of its 3D liver tissue product. Organovo achieved the milestone ahead of its April 2014 target date. Key opinion leaders are generally experts, in this case top research scientists, in a particular field whose opinions and publications will influence practice. Organovo expects KOLs to make recommendations on improvements to the tissue before launch and to influence peers through their reporting of their research results at conferences and through peer reviewed publications.
"This is an important milestone for Organovo R&D," said Organovo Chief Technology Officer and Executive Vice President of Research and Development Dr. Sharon Presnell. "In developing these tissues, we have gone through a careful set of research studies involving many individual tissues, and greatly increased our ability to produce them. By the end of January, we expect to have bioprinted nearly four hundred 3D Liver tissues during the month."
Organovo also introduced updated guidance on the timing of its product launch. Organovo had planned to launch its 3D Liver tissue product by the end of December 2014. It now expects to commence the commercial launch and start generating revenue through a services model prior to December 2014. "As pharmaceutical and biotechnology companies move to continue to outsource their R&D efforts," explained Keith Murphy, Organovo's chief executive officer, "our ability to deliver a service offering in addition to products will be critical to meet their needs and to enter the $7B preclinical research services market." The company anticipates that preclinical toxicology testing services can command prices in the high tens of thousands of dollars per compound for standard screening for liver alone.
Organovo's 3D Liver tissues exhibit several key features that remain stable over time:
-- Tissue-like cellular density;
-- Multi-layered architecture with multiple cell types positioned relative
to one another, reaching up to 500 microns thickness, with tissues
comprised of up to 20 cell layers;
-- Albumin production 5-9 times greater than matched 2D controls, suggesting
superior functionality;
-- Stable albumin production for over 40 days, fibrinogen and transferrin
production, and inducible cytochrome P450 enzymatic activities, including
CYP 1A2 and CYP 3A4;
-- Cholesterol biosynthesis, which has been demonstrated for the first time
in a multi-cellular 3D human liver system in vitro;
-- Evidence of the formation of tight junctions in the liver tissues,
demonstrated by cadherin and claudin staining by day 3 of tissue
formation; and
-- Demonstration of appropriate response to hepatotoxic insults from
acetaminophen, acetaminophen in combination with ethanol, and diclofenac.
Organovo plans to release additional data in 2014 on its 3D Kidney tissues and breast cancer tissues now in development. In December, Organovo demonstrated that its NovoGen bioprinted breast cancer tissues retain compartmentalized structures with interaction between stromal and cancer cells, along with formation of endothelial networks and differentiation of adipocytes. NovoGen 3D bioprinted constructs were demonstrated to be less susceptible to tamoxifen-induced toxicity than isolated 2D cancer cells when treated with the same dose of tamoxifen for the same duration, highlighting the potential utility of this model in identifying superior drugs with greater toxicity against complex, multicellular 3D tumor models.
Organovo also reminded investors of the continued availability of Organovo's December 5, 2013 online presentation. Organovo's Chairman and Chief Executive Officer, Keith Murphy, presented in a live interactive online forum that was a recorded event. The online content that can be accessed consists of a 30 min presentation as well as the text of a Q&A session that followed.
LINK: www.retailinvestorconferences.com > click on red "register / watch event now" button
The Company also reminded investors of its guidance to investors regarding "Short and Distort" articles.
I should of lightened up more than I did. The CCI started down on Dec. 24th. The MACD bearishly crossed over about Jan. 11th.
Wow the bottom really fell out more than I was expecting. Ouch
Thank you Gary. Already subscribed and taken a position on your discovery. Good luck and keep them coming.
I added more today but Scottrade didn't add to the shares I already have. They listed it as GGRGF# Now I have two separate positions of GGRGF. I don't understand.
GGRGF now has bid/ask on Scottrade. Scottrade customers can now buy.
GGRGF now has bid/ask on Scottrade. Picked some up today.
Scottrade will not let me buy it because there is no bid or ask showing up. It shows current price and volume though.
ExOne Under Fire After Scathing Report
http://www.engineering.com/3DPrinting/3DPrintingArticles/ArticleID/6253/ExOne-Under-Fire-After-Scathing-Report.aspx
ExOne Under Fire After Scathing Report
http://www.engineering.com/3DPrinting/3DPrintingArticles/ArticleID/6253/ExOne-Under-Fire-After-Scathing-Report.aspx
Citi initiated coverage on 3D Systems (NYSE: DDD) with a Buy rating and a price target of $60.00. Citi also initiated coverage on peer Stratasys (Nasdaq: SSYS) with a Buy and a price target of $125
Does anyone know about NAMII?
I was wondering if 3D Systems, ExOne and Stratasys are personally involved in any of the research there or do they just supply equipment.
The following is a list of equipment entrusted to date at the NAMII facility in Youngstown, Ohio.
Updated April 9, 2013
3D Systems: Cube — Material Extrusion (3D Printer)
3D Systems: SLS sPro 60 — Selective Laser Sintering
3D Systems: Thermojet — Wax Deposition
ExOne: M-Lab — Bonded Refractory Material
Renishaw: AM 250 — Selective Laser Melting
Stratasys: Fortus 400MC — Fused Deposition Modeling
Z-Corp: Z-Printer 310 — Bonded Plaster
Another start up 3D printing company getting crushed by DDD
http://www.engineering.com/3DPrinting/3DPrintingArticles/ArticleID/6096/Should-3D-Systems-Acquire-Formlabs.aspx
I totally agree. My 10 year old son has a custodial account in his name with scottrade that I manage and I bought in at $41 and sold at $65.80 only to watch it run to $75. But I was to excited to lock in his profit. I seem twice as smart on his account than I do mine. I hope it drops back down to $54 to re-buy for him. I make smarter trades for him than I do for myself. I do value your opinions on this particular stock. I may have to put his money into one of the other 3D plays if something looks attractive in the coming weeks though.
Took my son to the 3D printing expo in Chicago yesterday. He owns shares of DDD in a custodial account in his name. We couldn't get in because you have to be 18 or older. You would think DDD who anchors the expo would welcome the younger generation and would like to educate and peak their interests in this field. We were bummed that we couldn't get in.
The New "3D Space" of 3D Printing and 3D Scanning: A look at FARO Technologies
http://www.engineering.com/3DPrinting/3DPrintingArticles/ArticleID/5808/The-New-3D-Space-of-3D-Printing-and-3D-Scanning-A-look-at-FARO-Technologies.aspx
3D Printer Launching to Space Station in 2014
http://news.yahoo.com/3d-printer-launching-space-station-2014-215719508.html
X-Box One Prototyped with 3D Printer
Thought this was really cool.
http://www.engineering.com/3DPrinting/3DPrintingArticles/ArticleID/5752/X-Box-One-Prototyped-with-3D-Printer.aspx
3D-printed "bionic" ear hears better than the real thing
http://www.cbsnews.com/8301-205_162-57583308/3d-printed-bionic-ear-hears-better-than-the-real-thing/
There is someone coming up on Fox Business Channel that they are saying has 3D printed the first human ear. Don't know any more details yet.
Nice
I only picked up 7500 shares yesterday at the price you mentioned. Definitely not enough to crow about.It's all that got filled.
1/9/2013 1/14/2013 VTSI BOUGHT 7500 SHARES OF VTSI AT $0.037 ($8.39) $0.00 ($285.89)
Apparently Virtra had a few more sales that I never heard anything about. Excuse me if these are known and I just missed the news. This is from an article posted on 22 May 2012
Internationally, the following international customers that have purchased VirTra’s simulation products through a licensed/registered distributor: Nepal and Indonesia.
These new customers also acquired various simulator accessories, such as the patented THREAT-FIRE hostile return fire devices, tetherless recoil kits, and other simulator enhancements.
Aaron DeCorte, Vice-President of Sales of VirTra, expressed, “We are continuing to see growth of our sales to both domestic and international customers. Our revolutionary simulator training products continue to gain notoriety with consumers throughout the world.”